Investigator Sponsored Research (ISR) supports independent investigators and research organizations studying products, diseases, conditions, and technologies to advance medical and scientific knowledge.
Japan ISR removed mirabegron from eligible clinical products and removed mirabegron, enzalutamide, and ipragliflozin from material supply. Research priorities also changed across the remaining products, including removal of zolbetuximab combination/resistance topics and a new exclusion of enfortumab vedotin studies outside urothelial cancer.
Investigator-Sponsored Research (ISR) Program supports external investigators’ studies in Grifols’ therapeutic areas to advance scientific knowledge and address questions clinicians face in practice.
General Research Grants (GRG) - Astellas supports independent research leaders and organizations working on clinical research, registries and related projects to advance medical and scientific knowledge.
Investigator Initiated Studies (IIS) Program supports independent investigators and institutions studying Eisai products and compounds to address medical or scientific questions in neurology and oncology.
Investigator Initiated Studies (IIS) supports investigators conducting clinical studies of Genentech medicines to deepen understanding of treatments, improve patient care and generate disease-related research.
Investigator-Initiated Studies supports physicians and researchers conducting studies of AbbVie products and therapeutic interests to expand scientific knowledge and inform patient care.